Trial Profile
Investigation of Metformin in Patients With Castration Resistant Prostate Cancer in Combination With Enzalutamide vs. Enzalutamide Alone (IMPROVE TRIAL): A Randomized, Open Label, Phase II Trial
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 30 Jun 2023
Price :
$35
*
At a glance
- Drugs Enzalutamide (Primary) ; Metformin
- Indications Adenocarcinoma; Prostate cancer
- Focus Therapeutic Use
- Acronyms IMPROVE
- 26 Jun 2023 Status changed from active, no longer recruiting to discontinued.
- 13 Sep 2022 Primary endpoint has not been met. (Disease control (DC))
- 13 Sep 2022 Results presented at the 47th European Society for Medical Oncology Congress